Qingdao Huanghai Pharmaceutical Co., Ltd.

It is rapidly hydrolyzed into the active metabolite candesartan in the body. Candesartan is a selective angiotensin II receptor (AT1) antagonist. It antagonizes the vasoconstriction of angiotensin II by binding to the AT1 receptor of vascular smooth muscle, thereby reducing peripheral vascular resistance. It is also believed that candesartan can exert a certain antihypertensive effect by inhibiting the secretion of aldosterone by the adrenal gland. Candesartan does not inhibit kininase II and does not affect the degradation of bradykinin.

Regulates calcium influx into vascular smooth muscle cells; stimulates the synthesis of prostaglandins PGE2 and PGI2; reduces vascular hypersensitivity to vasopressors, thereby inhibiting vasoconstriction. This product has little or no effect on cardiac output, heart rate and rhythm when lowering blood pressure. Long-term use of this product rarely affects glomerular filtration rate or renal blood flow. This drug does not affect the metabolism of blood lipids and carbohydrates.

It affects dihydrofolate synthase, interfering with the first step of folic acid synthesis. When used in combination with trimethoprim, it can double block the folic acid metabolism of bacteria and enhance the synergistic antibacterial effect.

It acts on the second step of folic acid anabolism, selectively inhibits the action of dihydrofolate reductase, and when used in combination with sulfamethoxazole, it can double-block the folic acid metabolism of bacteria and enhance the synergistic antibacterial effect.

It can reduce myocardial oxygen consumption by dilating peripheral blood vessels, especially increasing venous blood volume, reducing the amount of blood returning to the heart, and reducing the preload and afterload of the heart; it can also promote the redistribution of myocardial blood flow, improve blood supply to the ischemic area, and play an anti-myocardial ischemia effect.

It acetylates the cyclooxygenase of platelets, reduces the generation of thromboxane A2, produces an irreversible inhibitory effect on TXA2-induced platelet aggregation, and also inhibits the phase II aggregation induced by ADP or adrenaline; it can also inhibit the platelet aggregation and release reaction and spontaneous aggregation caused by low concentrations of collagen, thrombin, antibody-antigen complexes, certain viruses and bacteria, thereby preventing the formation of thrombus. At high concentrations, it can also inhibit PG synthase in the blood vessel wall, reduce the synthesis of prostacyclin, and may promote the formation of thrombus.

It can catalyze the hydrolysis of various phosphates, promote or regulate human metabolism, help increase appetite, enhance physical fitness, and improve or cure diseases.

It can catalyze the hydrolysis of various phosphates, promote or regulate human metabolism, help increase appetite, enhance physical fitness, and improve or cure diseases.

It can catalyze the hydrolysis of various phosphates, promote or regulate human metabolism, help increase appetite, enhance physical fitness, and improve or cure diseases.

It can catalyze the hydrolysis of various phosphates, promote or regulate human metabolism, help increase appetite, enhance physical fitness, and improve or cure diseases.